SFM
RNAC icon

Sphera Funds Management’s Cartesian Therapeutics RNAC Stock Holding History

Sphera Funds Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25,070
Closed -$677K – 134
2024
Q2 		$677K Buy
25,070
+24,234
+2,899% +$578K 0.09% 108
2024
Q1 		$489K Sell
836
-24,235
-97% -$514K 0.07% 100
2023
Q4 		$519K Hold
25,071
– – 0.08% 89
2023
Q3 		$797K Sell
25,071
-42,879
-63% -$1.43M 0.15% 77
2023
Q2 		$2.28M Sell
67,950
-9,550
-12% -$342K 0.36% 68
2023
Q1 		$3.23M Buy
+77,500
New +$3.64M 0.54% 56
2018
Q1 		– Sell
-7,618
Closed -$2.24M – 135
2017
Q4 		$2.24M Hold
7,618
– – 0.26% 88
2017
Q3 		$4.17M Hold
7,618
– – 0.6% 46
2017
Q2 		$4.54M Hold
7,618
– – 0.77% 34
2017
Q1 		$3.27M Sell
7,618
-1,333
-15% -$561K 0.64% 46
2016
Q4 		$4.61M Sell
8,951
-537
-6% -$314K 1.17% 18
2016
Q3 		$3.99M Buy
+9,488
New +$3.71M 0.65% 36

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sphera Funds Management's RNAC Position: Q3 2024 in Review

Sphera Funds Management sold out of Cartesian Therapeutics (RNAC) in Q3 2024, closing a stake of 25,070 shares — an estimated $677K sold.

Sphera Funds Management first reported a position in RNAC in Q3 2016 and held it in 12 quarters. The position peaked at $4.61M in Q4 2016. 64 funds tracked by Wall St. Rank hold RNAC as of Q3 2024.

  • Sphera Funds Management reported no remaining Cartesian Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Sphera Funds Management sold 25,070 Cartesian Therapeutics shares in Q3 2024, an estimated $677K.
  • Sphera Funds Management first reported a position in Cartesian Therapeutics in Q3 2016 and held it in 12 quarters.
  • Sphera Funds Management's Cartesian Therapeutics position peaked at $4.61M in Q4 2016.
  • 64 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2024.

Based on Sphera Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.